Alpha Cognition (ACOG) to Release Earnings on Monday

Alpha Cognition (NASDAQ:ACOG) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $4.4050 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:30 PM ET.

Alpha Cognition Stock Down 2.2%

NASDAQ:ACOG opened at $5.71 on Monday. Alpha Cognition has a twelve month low of $3.75 and a twelve month high of $11.54. The firm has a market capitalization of $124.14 million, a price-to-earnings ratio of -4.17 and a beta of 2.55. The stock’s 50 day moving average price is $5.62 and its two-hundred day moving average price is $6.36.

Hedge Funds Weigh In On Alpha Cognition

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new position in Alpha Cognition during the second quarter worth approximately $112,000. Massar Capital Management LP acquired a new stake in shares of Alpha Cognition in the second quarter valued at approximately $116,000. Two Sigma Investments LP bought a new position in shares of Alpha Cognition during the 3rd quarter worth approximately $148,000. Boothbay Fund Management LLC increased its holdings in shares of Alpha Cognition by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 291,868 shares of the company’s stock worth $1,900,000 after acquiring an additional 28,392 shares during the last quarter. Finally, Connective Capital Management LLC acquired a new position in shares of Alpha Cognition during the 3rd quarter worth approximately $312,000.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Alpha Cognition in a research note on Friday, December 19th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $18.00.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.